Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast

被引:10
作者
Badve, Sunil S. [1 ]
Cho, Sanghee [2 ]
Gokmen-Polar, Yesim [1 ]
Sui, Yunxia [2 ]
Chadwick, Chrystal [2 ]
McDonough, Elizabeth [2 ]
Sood, Anup [2 ]
Taylor, Marian [3 ]
Zavodszky, Maria [2 ]
Tan, Puay Hoon [4 ]
Gerdes, Michael [2 ]
Harris, Adrian L. [3 ]
Ginty, Fiona [2 ]
机构
[1] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[2] GE Res, Niskayuna, NY 12309 USA
[3] Univ Oxford, Dept Oncol, Canc & Haematol Ctr, Oxford OX37LJ, England
[4] Singapore Gen Hosp, Dept Pathol, Singapore, Singapore
基金
美国国家卫生研究院;
关键词
INTERNATIONAL MULTICENTER; ACTIVE SURVEILLANCE; CANCER MORTALITY; LOCAL RECURRENCE; EXPRESSION; RISK; BIOPSY; WOMEN; OVERDIAGNOSIS; HETEROGENEITY;
D O I
10.1038/s41416-020-01216-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). METHODS: Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2. RESULTS: Only ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk (P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk (P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance (P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E-05; LOOCV AUC = 0.74, log-rank test P = 0.006). CONCLUSION: Multiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort.
引用
收藏
页码:1150 / 1159
页数:10
相关论文
共 40 条
[1]   Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications:: A comparative study with long follow-up [J].
Badve, S ;
A'Hern, RP ;
Ward, AM ;
Millis, RR ;
Pinder, SE ;
Ellis, IO ;
Gusterson, BA ;
Sloane, JP .
HUMAN PATHOLOGY, 1998, 29 (09) :915-923
[2]   Tumor Heterogeneity in Breast Cancer [J].
Badve, Sunil ;
Goekmen-Polar, Yesim .
ADVANCES IN ANATOMIC PATHOLOGY, 2015, 22 (05) :294-302
[3]   Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy [J].
Bartlett, John M. S. ;
Thomas, Jeremy ;
Ross, Douglas T. ;
Seitz, Robert S. ;
Ring, Brian Z. ;
Beck, Rodney A. ;
Pedersen, Hans Christian ;
Munro, Alison ;
Kunkler, Ian H. ;
Campbell, Fiona M. ;
Jack, Wilma ;
Kerr, Gillian R. ;
Johnstone, Laura ;
Cameron, David A. ;
Chetty, Udi .
BREAST CANCER RESEARCH, 2010, 12 (04)
[4]   A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk [J].
Bremer, Troy ;
Whitworth, Pat W. ;
Patel, Rakesh ;
Savala, Jess ;
Barry, Todd ;
Lyle, Stephen ;
Leesman, Glen ;
Linke, Steven P. ;
Jirstrom, Karin ;
Zhou, Wenjing ;
Amini, Rose-Marie ;
Warnberg, Fredrik .
CLINICAL CANCER RESEARCH, 2018, 24 (23) :5895-5901
[5]   70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].
Cardoso, F. ;
van't Veer, L. J. ;
Bogaerts, J. ;
Slaets, L. ;
Viale, G. ;
Delaloge, S. ;
Pierga, J. -Y. ;
Brain, E. ;
Causeret, S. ;
DeLorenzi, M. ;
Glas, A. M. ;
Golfinopoulos, V. ;
Goulioti, T. ;
Knox, S. ;
Matos, E. ;
Meulemans, B. ;
Neijenhuis, P. A. ;
Nitz, U. ;
Passalacqua, R. ;
Ravdin, P. ;
Rubio, I. T. ;
Saghatchian, M. ;
Smilde, T. J. ;
Sotiriou, C. ;
Stork, L. ;
Straehle, C. ;
Thomas, G. ;
Thompson, A. M. ;
van der Hoeven, J. M. ;
Vuylsteke, P. ;
Bernards, R. ;
Tryfonidis, K. ;
Rutgers, E. ;
Piccart, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729
[6]   Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy - Results from the Nurses' Health Study [J].
Collins, LC ;
Tamimi, RM ;
Baer, HJ ;
Connolly, JL ;
Colditz, GA ;
Schnitt, SJ .
CANCER, 2005, 103 (09) :1778-1784
[7]   Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial [J].
Cuzick, Jack ;
Sestak, Ivana ;
Pinder, Sarah E. ;
Ellis, Ian O. ;
Forsyth, Sharon ;
Bundred, Nigel J. ;
Forbes, John F. ;
Bishop, Hugh ;
Fentiman, Ian S. ;
George, William D. .
LANCET ONCOLOGY, 2011, 12 (01) :21-29
[8]  
Delou JMD, 2017, BREAST CANCER-TARGET, V9, P415, DOI 10.2147/BCTT.S131284
[9]   The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours [J].
El Ansari, Rokaya ;
Craze, Madeleine L. ;
Miligy, Islam ;
Diez-Rodriguez, Maria ;
Nolan, Christopher C. ;
Ellis, Ian O. ;
Rakha, Emad A. ;
Green, Andrew R. .
BREAST CANCER RESEARCH, 2018, 20
[10]   Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study [J].
Elshof, Lotte E. ;
Tryfonidis, Konstantinos ;
Slaets, Leen ;
van Leeuwen-Stok, A. Elise ;
Skinner, Victoria P. ;
Dif, Nicolas ;
Pijnappel, Ruud M. ;
Bijker, Nina ;
Rutgers, Emiel J. Th. ;
Wesseling, Jelle .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (12) :1497-1510